We Offer Worldwide Shipping
Login Wishlist

Levodopa

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-L2010

  • Specification : 98%

  • CAS number : 59-92-7

  • Formula : C9H11NO4

  • Molecular Weight : 197.19

  • PUBCHEM ID : 6047

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-L2010

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

197.19

Appearance

White crystalline powder

Botanical Source

seeds of Mucuna sempervirens Hemsl.

Structure Type

Others

Category

Standards;Natural Pytochemical;API

SMILES

C1=CC(=C(C=C1CC(C(=O)O)N)O)O

Synonyms

(-)-dopa/L-3,4-Dihydroxyphenylalanine/l-dop/Dopar/Alanine, 3- (3,4-dihydroxyphenyl)-, L-/3,4-Dihydroxy-L-phenylalanine/Doprin/L-4,5-Dihydroxyphenylalanine/Parda/Doparl/Tyrosine, 3-hydroxy-/Beldopa/3-Hydroxytyrosine/Levopa/Bendopa/(−)-dopa/L-DOPA/L-3-(3,4-dihydroxyphenyl)-Alanine/Levodopa/Ledopa

IUPAC Name

(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid

Density

1.5±0.1 g/cm3

Solubility

Aqueous acid

Flash Point

225.0±28.7 °C

Boiling Point

448.4±45.0 °C at 760 mmHg

Melting Point

276-278 °C(lit.)

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2922490000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:59-92-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

30000396

Title

Levodopa.

PMID

15553103

Abstract

The trial was designed as an open-label, post-authorisation safety study, aimed to complete the available information on adverse events and drug reactions to alpha-dihydroergocryptine (CAS 14271-05-7, alpha-DHEC). The study included 294 patients with idiopathic Parkinson’s disease who received levodopa (CAS 59-92-7, L-DOPA) and started taking alpha-DHEC (Cripar). Adverse events were analysed descriptively, Parkinson’s disease symptoms were documented using a questionnaire applied by the physicians. Patients were evaluated at study start and three and six months later, respectively. In 31 patients, 32 adverse events were observed, gastrointestinal and nervous system disorders being the most frequent. Dyskinesias, psychoses/hallucinations, sleep disturbances, and cardiovascular disorders were uncommon (< or = 1%). in total, 21 adverse events were classified as adverse drug reactions. In nearly 80 % of the cases, Parkinson symptoms had improved or completely vanished. Symptoms were unchanged in 16.7 % of patients and had worsened in 3.1%. The results confirm that the use of alpha-DHEC in combination therapy with levodopa in patients with Parkinson’s disease is a well-tolerated and efficacious treatment option.

Title

Alpha-dihydroergocryptine in the long-term therapy of Parkinson's disease.

Author

Mailland E1, Magnani P, Ottillinger B.

Publish date

2004;

PMID

10758773

Abstract

A standardized extract of ginkgo biloba (EGb 761) was evaluated in functional tests for monoamine oxidase (MAO) inhibition in mice: l-dihydroxyphenylalanine (CAS 59-92-7,1-DOPA) potentiation, tryptamine (CAS 61-54-1) potentiation, 5-hydroxytryptophan (CAS 4350-07-6,5-HTP) potentiation and phenylethylamine (CAS 64-04-0) potentiation. The doses investigated (25, 50 and 100 mg/kg p.o once daily for 5 days) were those known to possess anti-stress properties in other animal models. In contrast to the reference substances investigated (nialamide (CAS 51-12-7), clorgyline (CAS 17780-75-5) and 1-deprenyl (CAS 14611-52-01), EGb 761 did not exhibit any activity indicative of MAO inhibition. It was concluded that MAO inhibition was not the mechanism primarily responsible for EGb 761’s anti-stress activity.

Title

Evaluation of a ginkgo biloba extract (EGb 761) in functional tests for monoamine oxidase inhibition.

Author

Porsolt RD1, Roux S, Drieu K.

Publish date

2000 Mar;


Description :

L-DOPA is a natural form of DOPA used in the treatment of Parkinson's disease. L-DOPA is the precursor of dopamine and product of tyrosine hydroxylase.Target: Dopamine ReceptorL-DOPA (L-3,4-dihydroxyphenylalanine) is a chemical that is made and used as part of the normal biology of humans, some animals and plants. Some animals and humans make it via biosynthesis from the amino acid L-tyrosine. L-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine collectively known as catecholamines. L-DOPA can be manufactured and in its pure form is sold as apsychoactive drug with the INN levodopa; trade names include Sinemet, Parcopa, Atamet, Stalevo, Madopar, Prolopa, etc. As a drug it is used in the clinical treatment of Parkinson's disease and dopamine-responsive dystonia.L-DOPA crosses the protective blood-brain barrier, whereas dopamine itself cannot. Thus, L-DOPA is used to increase dopamine concentrations in the treatment of Parkinson's disease and dopamine-responsive dystonia. This treatment was made practical and proven clinically by George Cotzias and his coworkers, for which they won the 1969 Lasker Prize. In addition, L-DOPA, co-administered with a peripheral DDCI, has been investigated as a potential treatment for restless leg syndrome. However, studieshave demonstrated "no clear picture of reduced symptoms".